The endothelin system and its antagonism in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Chronic kidney disease (CKD) incidence is rising globally.
• Cardiovascular disease (CVD) is a major complication and cause of mortality in CKD patients.
• Effective treatments to slow CKD progression and mitigate cardiovascular risk are urgently needed.

Purpose of the Study:

• To explore the role of the endothelin (ET) system in the pathogenesis of CKD and CVD.
• To evaluate the potential therapeutic benefits of ET antagonists in managing CKD and associated cardiovascular risks.

Main Methods:

• Review of existing literature on the ET system's involvement in cardiovascular and renal physiology and pathology.
• Analysis of the mechanisms by which ET-1 contributes to hypertension, arterial stiffness, oxidative stress, inflammation, endothelial dysfunction, and atherosclerosis.
• Examination of preclinical and clinical data on ET antagonists in the context of CKD and CVD.

Main Results:

• ET-1 is a potent vasoconstrictor implicated in hypertension and arterial stiffness.
• The ET system contributes to oxidative stress, inflammation, endothelial dysfunction, and atherosclerosis, exacerbating CVD risk.
• ET antagonism may improve renal hemodynamics, reduce proteinuria, and potentially slow CKD progression, possibly synergistically with ACE inhibitors.

Conclusions:

• The ET system plays a significant role in the pathophysiology of both CKD and CVD.
• ET antagonists represent a promising therapeutic strategy for reducing cardiovascular risk and slowing CKD progression.
• Further research into combination therapies, such as ET receptor antagonists with ACE inhibitors, is warranted for managing CKD.